Addex Therapeutics Ltd.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company specializes in the discovery, development, and commercialization of novel small-molecule drugs known as allosteric modulators, which are orally available and target receptors and proteins essential for therapeutic intervention in neurological disorders. Its pipeline includes lead candidates such as dipraglurant, an mGlu5 negative allosteric modulator for post-stroke sensorimotor recovery and Parkinson's disease levodopa-induced dyskinesia; ADX71149, an mGlu2 positive allosteric modulator developed in collaboration with Janssen Pharmaceuticals for schizophrenia and anxious depression; and GABAB positive allosteric modulators for substance use disorder, chronic cough, pain, and overactive bladder. Addex Therapeutics also advances preclinical programs targeting mGlu7 for post-traumatic stress disorder, mGlu2 for mild neurocognitive disorders, mGlu4 for Parkinson's disease, and mGlu3 for neurodegenerative disorders. Operating as a single business segment in the biotechnology sector, the company focuses exclusively on central nervous system drug discovery and maintains collaborations for advancing its portfolio in the healthcare market.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Timothy Mark Dyer

Employees

3

Headquarters

Geneva, Switzerland

Website

www.addextherapeutics.com